The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.
Abstract
Significance: IL-1β is an immunomodulatory cytokine that is overexpressed in the brains of patients with Alzheimer’s disease (AD). The NLRP3 inflammasome is an intracellular complex that activates caspase-1, which processes the IL-1β and IL-18 precursors into active molecules. In this study, we used an APP/PS1 mouse model for AD, which confirms significant cognitive losses that are recovered in NLRP3-deficient mice, to evaluate the therapeutic potential of an orally bioavailable and safe NLRP3 inhibitor, OLT1177. OLT1177 ameliorated the phenotype in APP/PS1 mice, as evidenced by rescued spatial learning and memory in the Morris water maze test. Microglia were less activated, cortical plaques reduced, and plasma AD metabolic markers were normalized. OLT1177 is a potential therapeutic option for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4. The administration of oral OLT1177 in APP/PS1 animals for 3 mo significantly reduces microglia activation. (A–C) Evaluation of microglial cells by immunostaining of IBA-1 (IBA-1 in red, DAPI in blue) showed no significant differences in activation status of microglial cells between APP/PS1 animals treated with OLT1177 or without (n = 6 to 9, B; n = 12 to 18, C). (Scale bar in A, 100 µm.) (D and E) In addition the percentage of CD68 expressing cells, as an activation marker for microglial cells, was enhanced in CD11b+/CD45low gated cells of APP/PS1 mice treated with control food (WT vs. APP/PS1 P = 0.015, n = 4 to 5 animals). (F–H) Elevation of proinflammatory cytokines IL-1β, IL-6, and TNF-α was detected in brain homogenates of APP/PS1 mice (WT vs. APP/PS1 P = 0.019, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001, F; WT vs. APP/PS1 P = 0.039, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.01, G; APP/PS1 vs. APP/PS1 7.5 g/kg OLT1177 P = 0.011, H; n = 6 to 12 samples). (I) The amount of Aβ plaques was determined using immunostaining for IBA-1 and BAM-10 (clone for Aβ) (IBA-1 in green, DAPI in blue, BAM-10 in red). (Scale bar in I, 500 µm.) (J) Plaque load was lower in the cortex of the APP/PS1 animals fed with 7.5 g/kg OLT1177 compared to APP/PS1 animals (cortex [CX] P = 0.03; hippocampus [HC] P = 0.16, n = 6 in both groups). Data are presented as mean ± SEM. *P < 0.05 compared to WT, +P < 0.05, +++P < 0.001 compared to APP/PS1 CTRL.](https://figures.cochat.ai/paper-figures/6122e4acafc94eb79811544a2ca9b8a3/the-nlrp3-inflammasome-inhibitor-olt1177-rescues-cognitive-impairment-in-a-mouse-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in another study, the inhibition of NLRP3 by OLT1177 significantly improved cognitive impairment in a mouse model of Alzheimer’s disease [84].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · cited 3×
“A drastic increase in TNF-α levels has been shown to be toxic to cortical neurons (37).”
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 4×
“Heneka et al. (16) pointed out the important role of the NLRP3 inflammasome/caspase-1 axis in AD pathogenesis by demonstrating significant improvements (e.g., in cognition) in APP/PS1 mice (a mouse model for AD) when crossed with NLRP3 − / − animals.”
InfluentialThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441 · cited 2×
“Halle et al. (14) showed evidence of increased activation of the NLRP3 inflammasome in microglia cells due to A β , and in mice with complete NLRP3 inflammasome deletion by genetic manipulation, spatial memory impairment was prevented (16).”
(2015) · HAL · Cited by 2,238
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
Cytology & cellular pathology of the nervous system
Penfield, W. G. (1965) · Medical Entomology and Zoology · Cited by 1,035
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983 · cited 1×
“Maturation and release of IL-1 β in the brain is due to NLRP3 activation (16, 44).”
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 2×
“Under inflammatory conditions in the brain, glial cells, such as microglia, release cytokines (30, 36).”
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911 · cited 1×
“…are also involved in shaping neuronal connections during postnatal development and supporting structural plasticity during learning processes (61 – 63). del Río-Hortega (64) has described these cells as phagocytic cells of the CNS, and today it is believed that they are involved in the clearing…”
The genetic landscape of Alzheimer disease: clinical implications and perspectives
Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.117 · Cited by 863
A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease
Baik, S. H., Kang, S., Lee, W., Choi, H., Chung, S., Kim, J.-I., & Mook-Jung, I. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.005 · Cited by 843 · cited 1×
“Systems-wide metabolic reprogramming is a hallmark of neurodegenerative diseases and, in particular, AD (23 – 25).”
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World Journal · doi:10.1100/2012/756357 · Cited by 839 · cited 1×
“As such, microglia cells that are attracted to the A β plaques show a higher production of proinflammatory cytokines (67, 68).”
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744 · cited 1×
“The APP/ PS1 mouse line, in which A β plaques can already be found at the age of 4 to 6 mo and deficits in spatial learning are clearly visible at 8 mo, represents a reliable model (17, 31, 32).”
The role of microglia in amyloid clearance from the AD brain
Lee, C. Y. D., & Landreth, G. E. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0433-4 · Cited by 701
Microglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 679
Moser, M. B., Trommald, M., & Andersen, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12673 · Cited by 612 · cited 1×
“In addition, alterations in dendritic spine density and morphology have been shown to correlate with defects in synaptic plasticity and cognitive function (22).”
Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam, T., Carta, S., Tengesdal, I., Nemkov, T., D’Alessandro, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716095115 · Cited by 574
Self-citationNew insights on the role of microglia in synaptic pruning in health and disease
Hong, S., Dissing-Olesen, L., & Stevens, B. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.12.004 · Cited by 557 · cited 1×
“Microglia cells have been investigated for their potential role in the pathogenesis of neurodegenerative diseases (58, 59).”
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Elevated circulating tumor necrosis factor levels in Alzheimer's disease
Fillit, H., Ding, W., Buee, L., Kalman, J., Altstiel, L., Lawlor, B., & Wolf-Klein, G. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90490-k · Cited by 512
Krabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., Miller, K. R., Prokop, S., Kettenmann, H., & Heppner, F. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060921 · Cited by 478 · cited 2×
“On the other hand, microglia cells react very sensitively to inflammatory processes by changing their morphological shape and have been consequently described as having an “ activated ” phenotype (36, 65, 66).”
Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100620 · Cited by 473 · cited 1×
“Inhibition of IL-1 β signaling, however, contributes to disease-modifying benefits (41).”
Perez Ortiz, J. M., & Swerdlow, R. H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14585 · Cited by 426 · cited 2×
“Alteration of circulating levels of carboxylic acids is a recurring trait in pathologies associated with neuroinflammation and microglia activation like AD (26).”
Chen, Z., & Trapp, B. D. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13062 · Cited by 411
Coupling Krebs cycle metabolites to signalling in immunity and cancer
Ryan, D. G., Murphy, M. P., Frezza, C., Prag, H. A., Chouchani, E. T., O’Neill, L. A., & Mills, E. L. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0014-7 · Cited by 398 · cited 1×
“…were characterized by increases in several distinctive markers of AD, such as: Carboxylic acids (a circulating marker of mitochondrial dysfunction) (28), deaminated purines (e.g., allantoate), glutaminolysis (glutamine, glutamate), glutathione turnover metabolites (5-oxoproline), proteolysis…”
Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro
Lue, L., Rydel, R., Brigham, E. F., Yang, L., Hampel, H., Murphy, G. M., Brachova, L., Yan, S., Walker, D. G., Shen, Y., et al. (2001) · Glia · doi:10.1002/glia.1072 · Cited by 382 · cited 1×
“So far, several reports demonstrated increased IL-1 β expression in A β -plaque – associated microglia cells (40, 42, 43).”
Webers, A., Heneka, M. T., & Gleeson, P. A. (2020) · Immunology & Cell Biology · doi:10.1111/imcb.12301 · Cited by 367 · cited 1×
“Microglia cells have been investigated for their potential role in the pathogenesis of neurodegenerative diseases (58, 59).”
Murray, C. A., & Lynch, M. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02974.1998 · Cited by 359
Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome
Tejera, D., Mercan, D., Sanchez‐Caro, J. M., Hanan, M., Greenberg, D., Soreq, H., Latz, E., Golenbock, D., & Heneka, M. T. (2019) · The EMBO Journal · doi:10.15252/embj.2018101064 · Cited by 351
Tarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020568013953 · Cited by 349
Savonenko, A., Xu, G. M., Melnikova, T., Morton, J. L., Gonzales, V., Wong, M. P. F., Price, D. L., Tang, F., Markowska, A. L., & Borchelt, D. R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.022 · Cited by 346
Chronic microglial activation and progressive dopaminergic neurotoxicity
Block, M. L., & Hong, J.-S. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351127 · Cited by 322
Vallières, L., & Rivest, S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041668.x · Cited by 322
Klück, V., Jansen, T. L. T. A., Janssen, M., Comarniceanu, A., Efdé, M., Tengesdal, I. W., Schraa, K., Cleophas, M. C. P., Scribner, C. L., Skouras, D. B., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30065-5 · Cited by 311 · cited 10×
“IL-6 may indeed have an important role in AD as it was shown that genetic variation in the IL-6 gene resulted in a delayed onset of the disease (51), and studies suggest that IL-6 plays a role in the synthesis and expression of APP (52).”
InfluentialSelf-citationThe role of TNF and its receptors in Alzheimer's disease
Perry, R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00291-3 · Cited by 297
Microglia and the brain: Complementary partners in development and disease
Hammond, T. R., Robinton, D., & Stevens, B. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060509 · Cited by 288
Interleukin-1 mediates Alzheimer and Lewy body pathologies
Griffin, W. S. T., Liu, L., Li, Y., Mrak, R. E., & Barger, S. W. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-5 · Cited by 262
Apelt, J., & Schliebs, R. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03176-0 · Cited by 257
The NLRP3 Inflammasome in Alzheimer’s Disease
Tan, M.-S., Yu, J.-T., Jiang, T., Zhu, X.-C., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8475-x · Cited by 248
Booshehri, L. M., & Hoffman, H. M. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00638-z · Cited by 239
Dursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., Atasoy, İ. L., Alaylıoğlu, M., Araz, Ö. S., Önal, B., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.014 · Cited by 237
Hosseini, S., Wilk, E., Michaelsen-Preusse, K., Gerhauser, I., Baumgärtner, W., Geffers, R., Schughart, K., & Korte, M. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1740-17.2018 · Cited by 236 · cited 1×
“5, LIN) (72, 73).”
Self-citationTargeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E. W. G. M., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 233 · cited 3×
“Under inflammatory conditions in the brain, glial cells, such as microglia, release cytokines (30, 36).”
Self-citationIncreased Serum IL-1β Level in Alzheimer’s Disease and Mild Cognitive Impairment
Forlenza, O. V., Diniz, B. S., Talib, L. L., Mendonça, V. A., Ojopi, E. B., Gattaz, W. F., & Teixeira, A. L. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000255051 · Cited by 219
Guan, W., Steffen, B. T., Lemaitre, R. N., Wu, J. H. Y., Tanaka, T., Manichaikul, A., Foy, M., Rich, S. S., Wang, L., Nettleton, J. A., et al. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000208 · Cited by 209 · cited 1×
“Other metabolites like several polyunsaturated fatty acids were decreased in the bloodstream of APP/PS1 mice, further providing correlative evidence between AD and fatty acid metabolism (29).”
Minkeviciene, R., Ihalainen, J., Malm, T., Matilainen, O., Keksa‐Goldsteine, V., Goldsteins, G., Iivonen, H., Leguit, N., Glennon, J., Koistinaho, J., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05147.x · Cited by 208 · cited 2×
“However, no deficits were found at the age of 6 mo (34, 35).”
Papassotiropoulos, A., Bagli, M., Jessen, F., Bayer, T. A., Maier, W., Rao, M. L., & Heun, R. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199905)45:5<666::aid-ana18>3.0.co;2-3 · Cited by 186 · cited 1×
“IL-6 may indeed have an important role in AD as it was shown that genetic variation in the IL-6 gene resulted in a delayed onset of the disease (51), and studies suggest that IL-6 plays a role in the synthesis and expression of APP (52).”
Wohlford, G. F., Van Tassell, B. W., Billingsley, H. E., Kadariya, D., Canada, J. M., Carbone, S., Mihalick, V. L., Bonaventura, A., Vecchié, A., Chiabrando, J. G., et al. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000931 · Cited by 178
Lalonde, R., Kim, H. D., Maxwell, J. A., & Fukuchi, K. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.08.028 · Cited by 170
Toldo, S. A., Mauro, A. G., Cutter, Z., Tassell, B. W. V., Mezzaroma, E., Buono, M. G. D., Prestamburgo, A., Potere, N., & Abbate, A. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000658 · Cited by 169 · cited 1×
“OLT1177 was shown to have beneficial effects in a murine model for acute arthritis by suppressing joint inflammation and in addition reduces the infarct size after ischemia reperfusion injury in the mouse (45 – 47).”
Marchetti, C., Swartzwelter, B., Koenders, M. I., Azam, T., Tengesdal, I. W., Powers, N., de Graaf, D. M., Dinarello, C. A., & Joosten, L. A. B. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1664-2 · Cited by 164
Self-citationO’Leary, T. P., & Brown, R. E. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.01.039 · Cited by 156
Ringheim, G. E., Szczepanik, A. M., Petko, W. W., Burgher, K. L., Zhu, S. Z., & Chao, C. C. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00356-2 · Cited by 144
Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors
Powers, R. K., Culp-Hill, R., Ludwig, M. P., Smith, K. P., Waugh, K. A., Minter, R., Tuttle, K. D., Lewis, H. C., Rachubinski, A. L., Granrath, R. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12739-9 · Cited by 139
Self-citationCellular and System Biology of Memory: Timing, Molecules, and Beyond
Korte, M., & Schmitz, D. (2016) · Physiological Reviews · doi:10.1152/physrev.00010.2015 · Cited by 125 · cited 1×
“For this purpose, we analyzed synaptic plasticity at the Schaffer collateral pathway connecting the CA3 with the CA1 subregions, one of the most extensively studied synapses in the CNS, as reviewed in Korte and Schmitz (21).”
Genome-wide Association Studies in Alzheimer’s Disease: A Review
Tosto, G., & Reitz, C. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0381-0 · Cited by 123 · cited 1×
“Recently, there has been increased evidence supporting a central role of the immune system in the progression or even the origin of the disease (3 – 5).”
Alzheimer’s as a metabolic disease
Demetrius, L., & Driver, J. A. (2013) · Biogerontology · doi:10.1007/s10522-013-9479-7 · Cited by 115 · cited 1×
“Systems-wide metabolic reprogramming is a hallmark of neurodegenerative diseases and, in particular, AD (23 – 25).”
Damjanac, M., Bilan, A. R., Barrier, L., Pontcharraud, R., Cantereau, A., Hugon, J., & Page, G. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.050 · Cited by 114
Smith, M. J., & Koch, G. L. E. (1987) · Journal of Cell Science · doi:10.1242/jcs.87.1.113 · Cited by 92
Interleukin-1B polymorphism is associated with age at onset of Alzheimer’s disease
Sciacca, F. L., Ferri, C., Licastro, F., Veglia, F., Biunno, I., Gavazzi, A., Calabrese, E., Boneschi, F. M., Sorbi, S., Mariani, C. B., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00011-3 · Cited by 82 · cited 1×
“Many of these cytokines (e.g., IL-6, TNF-α , and IL-1 β ) are linked to the progression of AD (6, 10, 37).”
Hosseini, S., Michaelsen-Preusse, K., Grigoryan, G., Chhatbar, C., Kalinke, U., & Korte, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107666 · Cited by 74 · cited 1×
“5, LIN) (72, 73).”
Self-citationPlasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker
Peña-Bautista, C., Roca, M., Hervás, D., Cuevas, A., López-Cuevas, R., Vento, M., Baquero, M., García-Blanco, A., & Cháfer-Pericás, C. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.04.008 · Cited by 65 · cited 1×
“…markers of inflammation-induced purine deamination and proteolysis were increased in APP/PS1 mice — consistent with previous studies in AD (56, 57) — and normalized by OLT1177 at a dose of 7.5 g/kg. Similarly, OLT1177 decreased the levels of oxidant stress markers (e.g., the glutathione…”
InfluentialA Review on MS-Based Blood Biomarkers for Alzheimer’s Disease
Oeckl, P., & Otto, M. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00165-4 · Cited by 46
Association of interleukin 1β polymorphisms and haplotypes with Alzheimer's disease
Payão, S. L. M., Gonçalves, G. M., de Lábio, R. W., Horiguchi, L., Mizumoto, I., Rasmussen, L. T., Pinhel, M. A. D. S., Souza, D. R. S., Bechara, M. D., Chen, E., et al. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.012 · Cited by 37
A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques
Verbeek, M. M., Otte‐Höller, I., Wesseling, P., Nostrand, W. E. V., Sorg, C., de Waal, R. M. W., & Ruiter, D. J. (1995) · Acta Neuropathologica · doi:10.1007/bf00294811 · Cited by 33 · cited 1×
“Previous studies have shown that CD68 can be described as a microglia activation marker (69, 70), and CD68 has been reported to be elevated in microglial cells associated with A β plaques in AD mouse models (71).”
The NLRP3 Inflammasome as a Pharmacological Target
Marchetti, C. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000718 · Cited by 31
Self-citationYuan, H. D., Xia, Q., Ge, P., & Wu, S. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2237-0 · Cited by 21
Neuroinflammation and Alzheimer’s Disease
Eikelenboom, P. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5405-9_3 · Cited by 17
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“145 These results suggest that microglia respond to the pathology of AD.”
MethodInfluentialNLRP3 and pyroptosis blockers for treating inflammatory diseases
Coll, R. C., Schroder, K., & Pelegrín, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.003 · Cited by 755
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
“Aside from clinical trials, OLT1177 has recently been tested as a potential treatment for numerous disease states including AD, autoimmune encephalomyelitis, myocardial ischemia, arthritis, and more (Marchetti et al., 2018b; SánchezFernández et al., 2019; Toldo et al., 2019; Lonnemann et al., 2020).”
BackgroundCai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
“Dapansutrile (OLT1177), an orally available small molecule inhibitor for NLRP3 inflammasome which can silence caspase1 and IL-1b and has well tolerated and free side effects in humans, could rescue synaptic plasticity, suppress inimical microglia, and reduce the number of plaques in APP/PS1 mouse model for AD (59).”
BackgroundTargeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Metadata
- Authors
- Lonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M.
- Affiliations
- Technische Universität Braunschweig (DE)
- Helmholtz Centre for Infection Research (DE)
- University of Colorado Anschutz (US)
- Olatec (United States) (US)
- University of Colorado Denver (US)
- Radboud University Nijmegen (NL)
- Department of Cellular Neurobiology, Zoological Institute, Technische Universität Braunschweig, 38106 Braunschweig, Germany;
- Corresponding author
- Dinarello, Charles A.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-11-30
- Volume
- 117
- Issue
- 50
- Pages
- 32145-32154
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7749353
- OpenAlex
- W3108308610
- Cited by
- 298
- References
- 74
- Citations by year
- 2026: 51 · 2025: 53 · 2024: 50 · 2023: 56 · 2022: 55 · 2021: 33
- FWCI
- 21.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion, cc-by-nc-nd)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (AI15614)
- Deutsche Forschungsgemeinschaft (SFB854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, Alzheimer's disease, cognitive impairment, IL-1β, caspase-1, APP/PS1 mice, microglial activation, amyloid plaques, spatial learning and memory, anti-inflammatory therapy
- MeSH terms
- Behavior Observation Techniques, NLR Family, Pyrin Domain-Containing 3 Protein, Administration, Oral, Alzheimer Disease, Animals, Behavior, Animal, Cerebral Cortex, Disease Models, Animal, Humans, Male, Mice, Transgenic, Neuronal Plasticity, Nitriles, Sulfones, Amyloid beta-Protein Precursor, Microglia, Mice, Presenilin-1, Inflammasomes, Cognitive Dysfunction, Spatial Memory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.